Atlas Trials

EGFR L858R

6 clinical trials · Condition

Sort:Newest firstOldest first

◉ Watch EGFR L858R

RecordFirmDate
An Open-Label, Single-Arm, Dose-Escalation Phase I Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of EDB-102 in Patients With EGFR L858R-Mutant, Third-Generation TKI-Resistant Advanced Non-Small Cell Lung Cancer With Liver Metastases (NCT07461727)Cancer Institute and Hospital, Chinese Academy of Medical Sciences2026-02-10
A Prospective Cohort Study to Evaluate Molecular pRognostic Factors and Resistance Mechanisms to Osimertinib in Adjuvant Treatment of Completely Resected pIB-IIIA Non-small Cell Lung Carcinoma With Common EGFR Mutations (L858R and Del19) (NCT06053099)Intergroupe Francophone de Cancerologie Thoracique2024-01-22
HERTHENA-Lung02: A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI Therapy (NCT05338970)Daiichi Sankyo2022-07-08
Bevacizumab Combined With Double Doses of Icotinib in Advanced NSCLC Patients With EGFR L858R Mutation (NCT05263947)Tianjin Medical University Cancer Institute and Hospital2022-01-30
(HARMONY) Study of BLU-701 in EGFR-mutant NSCLC (NCT05153408)Blueprint Medicines Corporation2022-01-13
(SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC (NCT04862780)Blueprint Medicines Corporation2021-06-29

Track EGFR L858R automatically

Every clearance here is in the API, with alerts when new ones post.